Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 Dividend Yield % is 5.31% as of Aug. 01, 2026, which is 21% above its 10-year median of 4.39. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 85.71% on this metric.
As of today (2026-08-01), the Trailing Annual Dividend Yield of Australian Clinical Labs is 5.31%.
The historical rank and industry rank for Australian Clinical Labs's Dividend Yield % or its related term are showing as below:
ASX:ACL'
s Dividend Yield % Range Over the Past 10 Years
Min: 2.26 Med: 4.39 Max: 21.72
Current: 5.31
During the past 6 years, the highest Dividend Yield of Australian Clinical Labs was 21.72%. The lowest was 2.26%. And the median was 4.39%.
ASX:ACL's Dividend Yield % is ranked better than 85.71% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.85
vs ASX:ACL: 5.31
If a company's dividend payout ratio is too high, its dividend may not be sustainable. The dividend payout ratio of Australian Clinical Labs Ltd is 0.88, which seems too high.
During the past 6 years, the highest Dividend Payout Ratio of Australian Clinical Labs was 2.68. The lowest was 0.14. And the median was 0.78.
During the past 12 months, Australian Clinical Labs's average Dividends Per Share Growth Rate was 4.20% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 1.40% per year.
During the past 6 years, the highest 3-Year average Dividends Per Share Growth Rate of Australian Clinical Labs was 1.40% per year. The lowest was 1.40% per year. And the median was 1.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Australian Clinical Labs (ASX:ACL) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACL vs TMO, DHR, IDXX: Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Dividend Yield % falls into.
Australian Clinical Labs Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Australian Clinical Labs Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
AUD 0.037500
2026-03-12
2026-03-13
2026-03-31
Cash Dividend
semi-annually
AUD:AUD 1.000000
AUD 0.090000
2025-09-01
2025-09-02
2025-09-23
Cash Dividend
semi-annually
AUD:AUD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a Dividend Yield % of 5.31% as of Aug. 01, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Australian Clinical Labs and its competitors. This is 21% above median its historical median of 4.39. Over the past decade, Australian Clinical Labs' Dividend Yield % has ranged from 2.26 to 21.72. According to the industry distribution chart, Australian Clinical Labs ranks #9 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 14.3%.
Is Australian Clinical Labs' Dividend Yield % too high?
Australian Clinical Labs' current Dividend Yield % of 5.31% is 21% above median its 10-year median of 4.39. Over the past 10 years, this metric has ranged from a low of 2.26 to a high of 21.72. The Medical Diagnostics & Research industry median Dividend Yield % is 1.85. Australian Clinical Labs' value of 5.31% is 187% above this industry median. Based on the distribution chart, Australian Clinical Labs ranks #9 out of 63 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #9 out of 63 companies for Dividend Yield %. This places Australian Clinical Labs in the top 14% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.85. Australian Clinical Labs' value of 5.31% is 187% above this benchmark. Historically, Australian Clinical Labs' own Dividend Yield % has ranged from 2.26 to 21.72 over the past decade. While the company's 10-year median is 4.39 vs. the industry median of 1.85, Australian Clinical Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Diagnostics & Research company?
The median Dividend Yield % among Medical Diagnostics & Research companies is 1.85, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Dividend Yield % of 5.31% is 187% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Yield % is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Dividend Yield % is 5.31%, which is 21% above median its own 10-year median of 4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Dividend Yield % is 5.31%, which is 21% above median its 10-year median of 4.39 and 187% above the Medical Diagnostics & Research industry median of 1.85. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Dividend Yield % is 5.31% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
Dividend Yield %: 5.31% (21% above median its 10-year median of 4.39)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 187% above the Medical Diagnostics & Research median (#9 of 63)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
